Ergothioneine Cognition Randomized Trial: What the Evidence Says

Quick Answer

Ergothioneine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Cognitive frailty not only affects the quality of life of older adults but also significantly increases the risk of severe adverse outcomes such as dementia and disability. [Gede Arjun M. M. I. (2025); evidence level 3]
• Research has demonstrated that ERGO exhibits significant protective effects against 7-ketocholesterol (7KC)-induced mitochondrial damage in human brain endothelial cells, as evidenced by improved cell viability, reduced intracellular calcium levels, decreased reactive oxygen species, and modulated expression of inflammatory markers. [Gede Arjun M. M. I. (2025); evidence level 3]
• This is particularly important for at-risk populations such as Apolipoprotein E ε4 allele carriers, those with a family history of dementia, and those at an early stage of cognitive decline, known as Subjective Cognitive Decline (SCD). [Shan Jiatong (2025); evidence level 4]
• Without early intervention, these at-risk populations groups are likely to progress to dementia. [Shan Jiatong (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For ergothioneine cognition randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Gede Arjun M. M. I. (2025). Advances and prospects of ergothioneine in the treatment of cognitive frailty. DOI: 10.1080/07853890.2025.2555742. PMCID: PMC12416020. PMID: 40914903. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12416020/
• Shan Jiatong (2025). Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community. DOI: 10.3389/fnagi.2025.1588493. PMCID: PMC12183302. PMID: 40552321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12183302/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.